Protocol Ledger

NCT05661188 · Phase II · COMPLETED

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)

Interventional Phase II clinical trial protocol NCT05661188 sponsored by Grupo Espanol Multidisciplinario del Cancer Digestivo in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-14 Enrollment: 45 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05661188
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)45 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05661188
Protocol FieldVerified Registry Value
NCT IdentifierNCT05661188
Consolidated Lead SponsorGrupo Espanol Multidisciplinario del Cancer Digestivo
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment45 participants (ACTUAL)
Registered Start Date2023-02-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI